mitoaction.org valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for mitoaction.org:
1. POST https://agentwebmap.com/v1/sites/mitoaction.org/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://mitoaction.org/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/mitoaction.org/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/mitoaction.org).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

MitoAction

Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T11:23:34.666Z. Cached copy (size limited) · Source on mitoaction.org

# MitoAction

> Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease

> Generated by All in One SEO Pro v5.0.3, this is an llms.txt file, used by LLMs to index the site.

## Sitemaps

- [XML Sitemap](https://www.mitoaction.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://www.mitoaction.org/news/)
- [MitoAction and The POLG Foundation to Co-HostExternally-Led Patient-Focused Drug DevelopmentMeeting on POLG-Related Disorders](https://www.mitoaction.org/mitoaction-and-the-polg-foundation-to-co-hostexternally-led-patient-focused-drug-developmentmeeting-on-polg-related-disorders/): October 20, 2026 Virtual PFDD Meeting Scheduled for November 17, 2026 Novi, MI — October 20, 2026 — MitoAction and The POLG Foundation are proud to announce that they will co-host an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting focused on POLG-Related Disorders. The virtual meeting will be held on Tuesday, November 17, 2026, and is
- [Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders](https://www.mitoaction.org/pretzel-therapeutics-receives-fda-fast-track-designation-for-px578-for-the-treatment-of-polg-mediated-primary-mitochondrial-disorders/): September 22, 2026 Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders Fast Track Designation adds to recent regulatory momentum for PX578 – Phase 2 (POLARIS) study initiation planned for late 2026 – WALTHAM, Mass. – Tuesday, September 22, 2026 – Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing
- [Mighty Therapeutics Partners with the POLG Foundation to Develop Novel Preclinical Model for POLG Mitochondrial Disorders and Parkinson’s Disease](https://www.mitoaction.org/mighty-therapeutics-partners-with-the-polg-foundation-to-develop-novel-preclinical-model-for-polg-mitochondrial-disorders-and-parkinsons-disease/): September 15, 2026 Trailblazing approach to leverage learnings from rare POLG disorders to inform development for Parkinson's and other age-related neurological diseases NEEDHAM, Mass., Sept. 15, 2026 /PRNewswire/ -- Mighty Therapeutics (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, is celebrating World Mitochondrial
- [Mighty Therapeutics to Develop MYTX-255 for Fatty Acid Oxidation Disorders.](https://www.mitoaction.org/enabling-studies-of-mytx-255-a-mitochondrial-targeted-therapeutic-candidate/): September 9, 2026 New data presented in long-chain fatty acid oxidation disorders at INFORM 2026 support development of Company's third mitochondrial-targeted candidate NEEDHAM, Mass., Sept. 9, 2026 /PRNewswire/ -- Mighty Therapeutics (the "Company" or "Mighty"), a commercial-stage b
…

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=mitoaction.org · GET /v1/domain/mitoaction.org · this page as Accept: application/json or text/markdown · MCP lookup_domain